As shown in Table 2 and Figure 4C–4D VLX60 exhibited a trend towards enhanced activity against both KRAS and BRAF mutated tumor cells from patients with colorectal cancer although the difference was not statistically significant (KRAS and BRAF mutation status was only available in 16 patient samples). This evidence concerns the gene KRAS and colorectal cancer.